报价延迟最少15分钟:2025/08/25 03:41 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.61 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.81/-1.39
|
|
企业价值
438.46M
|
| 资产负债 |
|
每股账面净值
1.69
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/08/25 03:41 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mentalhealth challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360. |
